professionally run and on-track, page-8

Watching this one like a hawk, but admittedly it is quiet (for now) and we need to wait a little longer.

The main upcoming news is FDA approval for the trial. My expectation for this is sometime in March but perhaps April.

I also anticipate forward movement on European regulatory approval, again a couple of months down the track.

I am personally very confident about the quality of the underlying technology and I like management and their approach.

This stock is unusually inexpensive but the catalysts I am waiting for are a month or two away rather than a matter of weeks.

The current share price, in my view, will look very attractive in Q2 and Q3 2014. I for one am prepared to sit, wait and be patient.